Lantheus Holdings (NASDAQ: LNTH) is weighing a potential sale after receiving a takeover offer from private-equity-backed Curium Pharma that would value the radiopharmaceutical company at about $7 billion, according to a Bloomberg report on May 22, 2026. The stock surged 9.0% on Friday to close at a record $103.00, capping a week in which the market re-rated one of the few remaining mid-cap, U.S.-listed pure plays in nuclear medicine.
If a deal materializes at the reported price, it would be the largest radiopharmaceutical M&A transaction since Bristol Myers Squibb agreed to buy RayzeBio for $4.1 billion in December 2023 — and the first time a sponsor-backed strategic, rather than a Big Pharma buyer, sits at the top of the league table for the sector.
What’s on the table
Lantheus has not filed an 8-K confirming the approach, and neither company has issued a public statement. Bloomberg, citing people familiar with the matter, reported that Curium has approached the Bedford, Massachusetts-based company and that Lantheus is evaluating its options. At an implied $7 billion equity value against Lantheus’s pre-leak market capitalization of roughly $6.1 billion (~65 million shares outstanding × $94.47 prior close), the indicated bid suggests a premium of approximately 14% above Thursday’s close — well below the 30%+ premiums that have characterized recent radioligand-therapy deals.
That gap matters. Lantheus’s board does not have to engage with Curium; the stock’s Friday jump signals investors expect the price to move higher if a process opens up. Whether Curium can stretch — or whether a strategic with a larger balance sheet steps in — will likely define the next phase.
Lantheus enters from a position of strength
Lantheus reported first-quarter 2026 results on May 7, 2026, and the print was solid even if growth has flattened. Worldwide revenue rose 1.2% year-over-year to $377.3 million, GAAP fully diluted EPS climbed 76.5% to $1.80, and the company reaffirmed full-year revenue guidance of $1.4–$1.45 billion with adjusted EPS of $5.00–$5.25 (Form 8-K, May 7, 2026).
| Lantheus Q1 2026 results | Q1 2026 | Q1 2025 | % change |
|---|---|---|---|
| Worldwide revenue ($M) | 377.3 | 372.8 | +1.2% |
| PYLARIFY sales ($M) | 240.9 | 257.6 | −6.5% |
| DEFINITY sales ($M) | 84.6 | 79.2 | +6.8% |
| Neuraceq sales ($M) | 35.4 | n/d | — |
| GAAP diluted EPS | $1.80 | $1.02 | +76.5% |
| Adjusted diluted EPS | $1.46 | $1.53 | −4.6% |
| Cash and equivalents ($M) | 498.6 | 359.1 (12/31/25) | +38.8% |
PYLARIFY — the prostate-specific membrane antigen (PSMA) PET imaging agent that established Lantheus as a leader in prostate-cancer diagnostics — slipped 6.5% in the quarter as the company prepares the geographic rollout of a successor formulation, PYLARIFY TruVu, which received FDA approval in Q1 and is set for a phased launch beginning Q4 2026. DEFINITY, the ultrasound-enhancing agent used in echocardiography, continued to grind higher at +6.8%. Cash climbed to $498.6 million following the $31.4 million sale of the legacy SPECT business to SHINE Technologies on January 1, 2026, leaving Lantheus with $750 million of undrawn revolver capacity.
On the May 7 call, CEO Mary Anne Heino flagged the company would “remain disciplined in our capital deployment, prioritizing radiodiagnostics while evaluating the best path to maximize value from our radiotherapeutic assets.” Two weeks later, that “best path” appears to include selling the whole company.
Why Curium — and why now
Curium Pharma describes itself as “the world’s leading nuclear medicine company,” with operations in more than 60 countries (company profile). Curium is privately held and PE-backed; the company has previously been linked to IPO and sale processes that did not materialize, and it has long been viewed as a logical consolidator of mid-cap nuclear-medicine assets.
For a financial sponsor, Lantheus’s appeal is straightforward:
- Cash generation. $121.9 million of Q1 free cash flow on $377 million of revenue annualizes to a high-teens FCF margin — useful when you are stapling debt.
- Defensible diagnostics franchise. PYLARIFY and DEFINITY are reimbursed, branded products with limited near-term genericization risk; PYLARIFY TruVu extends the moat.
- Optionality on therapeutics. Tentative FDA approval for PNT2003 — the first U.S. radioequivalent to Lutetium Lu 177 dotatate for gastroenteropancreatic neuroendocrine tumors — gives a buyer a near-term entry into radioligand therapy without the dilution of acquiring a clinical-stage developer.
- Manufacturing. Sponsor consolidation of Curium’s existing nuclear-pharmacy network with Lantheus’s PYLARIFY supply could create scale benefits at a time when isotope supply (Mo-99, Lu-177, Ac-225) is a sector-wide bottleneck.
Radiopharm M&A: where this deal would sit
Big Pharma’s interest in radiopharmaceuticals dates to Novartis’s acquisition of Advanced Accelerator Applications in early 2018, which delivered Pluvicto and turned the modality into a billion-dollar oncology franchise. The last 30 months have brought a steady drumbeat of sector deals — each smaller than a Curium-Lantheus tie-up would be.
| Selected radiopharmaceutical M&A deals | Buyer | Target | Value | Announced |
|---|---|---|---|---|
| PSMA / oncology platform | Novartis | Advanced Accelerator Applications | $3.9B | Oct 2017 |
| Lu-177-PSMA-617 (now Pluvicto) | Novartis | Endocyte | $2.1B | Oct 2018 |
| Lu-177 manufacturing + PNT2002 | Eli Lilly | POINT Biopharma | $1.4B | Oct 2023 |
| Actinium-225 platform | Bristol Myers Squibb | RayzeBio | $4.1B | Dec 2023 |
| FAP-α targeted radioligands | AstraZeneca | Fusion Pharmaceuticals | ~$2.0B | Mar 2024 |
| Commercial diagnostics + therapeutic optionality | Curium Pharma (reported) | Lantheus Holdings | ~$7.0B | May 2026 (reported) |
Across these five precedents, the median announced value sits near $2.1 billion. A consummated $7 billion Lantheus deal would more than triple the median and represent the first commercial-scale radiopharmaceutical transaction — i.e., a target with meaningful revenue, profitability, and a launched product, rather than a clinical-stage developer with optionality.
What investors should watch next
- An 8-K confirmation. If Lantheus’s board has formally received and is reviewing a proposal, an 8-K under Item 8.01 — or a public statement that it has commenced a strategic review — would typically follow within days. Silence beyond a week tends to indicate a board declined to engage at the indicated price.
- Counterbidders. Sanofi, GE Healthcare, Bayer, and Siemens Healthineers have all flirted with deeper exposure to nuclear medicine. Each is a plausible interloper if Curium’s bid forces a sale process. Bayer is already a Lantheus partner, per Lantheus’s strategic-alliances disclosure (company profile).
- Premium math. The implied 14% premium over Thursday’s close is light against the 30%+ benchmarks set by RayzeBio (BMS paid a ~104% premium per share to undisturbed) and Fusion Pharmaceuticals (~97% premium). Either Curium has to raise, or another bidder has to emerge.
- Antitrust review. Curium owns the largest U.S. radiopharmacy network; Lantheus runs the dominant PSMA imaging franchise. Vertical integration of supply and demand in PET diagnostics would draw FTC scrutiny in the U.S. and DG Comp review in Europe.
- PNT2003 timing. Lantheus disclosed on May 7 that PNT2003 launch timing is contingent on the expiration of a 30-month Hatch-Waxman stay and the related litigation. A pending litigation outcome could meaningfully change the assumptions a buyer underwrites.
The bigger picture
Capital-markets watchers should read this story on two levels. At the asset level, it confirms that radioligand therapy has crossed the threshold from clinical-stage curiosity to a fully-fledged oncology modality worth paying multi-billion-dollar premia for. At the structural level, it marks the first time a private-equity-backed industry consolidator — rather than a Big Pharma strategic — is setting the price for a U.S.-listed radiopharm leader. If Curium closes, the sector has a new center of gravity that does not answer to Basel, Indianapolis, or New York City. If the deal breaks because a strategic outbids, the message is even cleaner: Big Pharma views nuclear medicine as a category it cannot afford to lose.
Either way, Lantheus shareholders are unlikely to wake up on Monday morning to silence.
Sources
- Bloomberg — Lantheus Weighs Sale After Takeover Bid from Curium Pharma (May 22, 2026)
- Lantheus Holdings — Q1 2026 press release (Form 8-K Ex-99.1, May 7, 2026)
- SEC EDGAR — Lantheus Holdings recent 8-K filings
- Curium Pharma — About
- Advanced Accelerator Applications — company history
- Endocyte — company history
- Bristol Myers Squibb — RayzeBio acquisition
- Lantheus Holdings — company profile
Disclosure: This article was produced with AI assistance and reviewed before publication. It is for informational purposes only and is not investment advice.